Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
20 10 2020
Historique:
received: 24 08 2020
revised: 14 10 2020
accepted: 15 10 2020
entrez: 23 10 2020
pubmed: 24 10 2020
medline: 6 11 2020
Statut: epublish

Résumé

RT-PCR on nasopharyngeal (NPS)/oropharyngeal swabs is the gold standard for diagnosis of SARS-CoV-2 infection and viral load monitoring. Oral fluid (OF) is an alternate clinical sample, easy and safer to collect and could be useful for COVID-19 diagnosis, monitoring viral load and shedding. Optimal assay conditions and analytical sensitivity were established for the commercial Simplexa™ COVID-19 Direct assay adapted to OF matrix. The assay was used to test 337 OF and NPS specimens collected in parallel from 164 hospitalized patients; 50 bronchoalveolar lavage (BAL) specimens from a subgroup of severe COVID-19 cases were also analysed. Using Simplexa™ COVID-19 Direct on OF matrix, 100% analytical detection down to 1 TCID50/mL (corresponding to 4 × 10 Simplexa™ COVID-19 Direct assays on OF have high sensitivity and specificity to detect SARS-CoV-2 RNA and provide an alternative to NPS for diagnosis and monitoring SARS-CoV-2 shedding.

Sections du résumé

BACKGROUND
RT-PCR on nasopharyngeal (NPS)/oropharyngeal swabs is the gold standard for diagnosis of SARS-CoV-2 infection and viral load monitoring. Oral fluid (OF) is an alternate clinical sample, easy and safer to collect and could be useful for COVID-19 diagnosis, monitoring viral load and shedding.
METHODS
Optimal assay conditions and analytical sensitivity were established for the commercial Simplexa™ COVID-19 Direct assay adapted to OF matrix. The assay was used to test 337 OF and NPS specimens collected in parallel from 164 hospitalized patients; 50 bronchoalveolar lavage (BAL) specimens from a subgroup of severe COVID-19 cases were also analysed.
RESULTS
Using Simplexa™ COVID-19 Direct on OF matrix, 100% analytical detection down to 1 TCID50/mL (corresponding to 4 × 10
CONCLUSIONS
Simplexa™ COVID-19 Direct assays on OF have high sensitivity and specificity to detect SARS-CoV-2 RNA and provide an alternative to NPS for diagnosis and monitoring SARS-CoV-2 shedding.

Identifiants

pubmed: 33092065
pii: v12101184
doi: 10.3390/v12101184
pmc: PMC7589602
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Covid-19 aAPC vaccine 0
RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Infect. 2020 Sep;81(3):e48-e50
pubmed: 32593658
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect. 2020 Aug;81(2):e145-e147
pubmed: 32504740
J Infect Chemother. 2020 Oct;26(10):1086-1089
pubmed: 32571647
J Infect. 2020 Jul;81(1):e45-e50
pubmed: 32298676
Eur J Dent. 2020 Jun 03;:
pubmed: 32492721
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32703816
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
J Clin Virol. 2020 Jul;128:104416
pubmed: 32388470
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Front Med (Lausanne). 2020 Aug 04;7:465
pubmed: 32903849
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32317257
J Clin Virol. 2020 Jun;127:104384
pubmed: 32361285
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32636214
Clin Microbiol Infect. 2020 May 15;:
pubmed: 32422408
Clin Microbiol Infect. 2020 Jul;26(7):954-956
pubmed: 32229288

Auteurs

Licia Bordi (L)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Giuseppe Sberna (G)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Eleonora Lalle (E)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Pierluca Piselli (P)

Epidemiology Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Francesca Colavita (F)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Emanuele Nicastri (E)

Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Andrea Antinori (A)

Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Evangelo Boumis (E)

Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Nicola Petrosillo (N)

Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Luisa Marchioni (L)

Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Giulia Minnucci (G)

R&D Department, DiaSorin Molecular LLC, Cypress, CA 90630, USA.

Elena D'Agostini (E)

R&D Department, DiaSorin Molecular LLC, Cypress, CA 90630, USA.

Concetta Castilletti (C)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Franco Locatelli (F)

Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00165 Rome, Italy.

Alimuddin Zumla (A)

Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London W1T 7DN, UK.

Giuseppe Ippolito (G)

Scientific Direction, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Maria Rosaria Capobianchi (MR)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH